Oric Pharmaceuticals Inc (ORIC) Stock Price, Quote & News

Company Profile

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 2...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 388 5600

Website: www.oricpharma.com

Address:

240 East Grand Avenue, 2nd Floor, South San Francisco, United States

SK_Trading_Substack Jun. 11 at 2:53 PM

$AKRO $XGN $GSHD $ORIC $LOMA Today's most likely to have a big week.

0 · Reply

AnomalyDetective Jun. 7 at 2:00 PM

The Market Momentum Gauge signals turned positive in Week 18 and we have seen a sharp increase in MDA breakout gains with +99.57% YTD avg cumulative returns trading in the positive signals. Including $ORIC $BDTX $APPS $ALTS $PDYN and others we have had 12 selections gain over 20% and as high as +111% in less than a week in just the last 4 weeks. Additional free breakouts from the automated website available here: http://top.vmbreakouts.com New Week 24 MDA selections for next week: https://seekingalpha.com/mp/1201-value-momentum-breakouts/articles/6165533-june-mda-breakout-stocks-week-24-and-highlighted-top-gainers

0 · Reply

AnomalyDetective Jun. 6 at 1:51 PM

$PDYN +39.8% $ALTS +36.9% from Week 22 still flying high with this Week 23 MDA picks up +10.8% led by $ORIC and $BDTX as the $LABU breakout takes off for the Active #ETF sector portfolio +32.3% YTD. Credit: http://vmbreakouts.com with free breakout picks at http://top.vmbreakouts.com

0 · Reply

Rounderssss4 Jun. 4 at 2:30 PM

$ORIC

0 · Reply

metalcook Jun. 2 at 1:44 PM

$ORIC how does this compare to $JANX and $VIR?

1 · Reply

GSP Jun. 2 at 1:00 PM

Video title should say June 2nd, not the 1st. Apologies. $SPY $RRGB $ORIC $TNGX $LTBR

0 · Reply

leon_dedrick May. 30 at 6:39 PM

$ORIC This will quietly creep over 10.00 the next month

0 · Reply

PenkeTrading May. 30 at 12:00 PM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Oric Pharmaceuticals Inc. Is that bullish or bearish? $ORIC #Oric #RsiOverbought #NASDAQ

0 · Reply

GSP May. 30 at 11:34 AM

$SPY $ZEO $ORIC $U $SGBX

0 · Reply

PaulLaurent May. 30 at 5:48 AM

4:00am EST Watchlist 🌅 part two $INAB – AH runner catching volume after recent lows. Traders watching for continuation in early premarket. 🚀 $PATH – UiPath reported Q1 fiscal 2026 revenue of $ 335M, up 16% YoY. Beat EPS and raised FY guidance. AI theme keeps it in play. 🤖📈 $SPRO – Speculative biotech with recent upside momentum. Potential for multi-day continuation if volume sustains. 🧬 $ORIC – On watch after multiple updates this week including new private placement and promising clinical data. 🔬💰 $ZEO – Recent acquisition of Heliogen still in focus. Traders watching for clean setup following news digestion. ☀️ 📉 Market tone: Eyes on tech and biotech catalysts. Expect early volatility if momentum builds off AH action.

0 · Reply

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 29, 2025, 11:15 AM EDT - 18 days ago

ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

May 28, 2025, 4:05 PM EDT - 19 days ago

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

May 28, 2025, 4:05 PM EDT - 19 days ago

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

May 27, 2025, 4:30 PM EDT - 20 days ago

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

May 27, 2025, 8:00 AM EDT - 20 days ago

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

May 5, 2025, 4:05 PM EDT - 6 weeks ago

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

Apr 28, 2025, 4:30 PM EDT - 7 weeks ago

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 22, 2025, 9:15 AM EDT - 7 weeks ago

ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech

Mar 25, 2025, 4:30 PM EDT - 2 months ago

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Feb 25, 2025, 4:15 PM EST - 3 months ago

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

Feb 18, 2025, 4:05 PM EST - 4 months ago

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

Jan 13, 2025, 8:05 AM EST - 5 months ago

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

Jan 6, 2025, 4:15 PM EST - 5 months ago

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 4:30 PM EST - 5 months ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 1, 2024, 4:30 PM EDT - 8 months ago

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 9, 2024, 4:15 PM EDT - 8 months ago

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 26, 2024, 4:05 PM EDT - 10 months ago

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 12, 2024, 4:05 PM EDT - 11 months ago

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

Aug 5, 2024, 4:15 PM EDT - 11 months ago

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

Jul 17, 2024, 1:00 PM EDT - 11 months ago

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

Jul 16, 2024, 4:59 PM EDT - 11 months ago

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

May 6, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

Apr 15, 2024, 4:15 PM EDT - 1 year ago

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

Apr 8, 2024, 8:00 AM EDT - 1 year ago

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 13, 2024, 8:19 AM EDT - 1 year ago

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

Mar 11, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

Mar 6, 2024, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Feb 14, 2024, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

Jan 22, 2024, 8:30 AM EST - 1 year ago

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

Jan 8, 2024, 8:30 AM EST - 1 year ago

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

Jan 2, 2024, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

$Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development$

Dec 11, 2023, 12:00 PM EST - 1 year ago

Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

Dec 9, 2023, 8:00 AM EST - 1 year ago

ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting

Nov 6, 2023, 4:10 PM EST - 1 year ago

ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

Nov 2, 2023, 9:00 AM EDT - 1 year ago

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Oct 21, 2023, 7:30 AM EDT - 1 year ago

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

Oct 17, 2023, 4:30 PM EDT - 1 year ago

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

Sep 20, 2023, 4:30 PM EDT - 1 year ago

ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference

Aug 10, 2023, 4:05 PM EDT - 2 years ago

ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

Jul 27, 2023, 3:57 PM EDT - 2 years ago

You can still run with the stock market's bulls, but watch the exits

CCL CRON EEM EW KOPN PFG PRU

Jun 26, 2023, 8:30 AM EDT - 2 years ago

ORIC Pharmaceuticals Announces $85 Million Private Placement Financing

May 31, 2023, 4:10 PM EDT - 2 years ago

ORIC Pharmaceuticals to Participate in the Jefferies Healthcare Conference

May 8, 2023, 4:05 PM EDT - 2 years ago

ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

Apr 25, 2023, 4:30 PM EDT - 2 years ago

ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference

Apr 18, 2023, 4:15 PM EDT - 2 years ago

ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Mar 16, 2023, 4:05 PM EDT - 2 years ago

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates

Mar 15, 2023, 12:47 AM EDT - 2 years ago

ORIC Pharma: Small Pfizer Deal, Cash, And A Set Of Very Early Stage Assets

Mar 14, 2023, 4:30 PM EDT - 2 years ago

ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting

SK_Trading_Substack Jun. 11 at 2:53 PM

$AKRO $XGN $GSHD $ORIC $LOMA Today's most likely to have a big week.

0 · Reply

AnomalyDetective Jun. 7 at 2:00 PM

0 · Reply

AnomalyDetective Jun. 6 at 1:51 PM

0 · Reply

Rounderssss4 Jun. 4 at 2:30 PM

$ORIC

0 · Reply

metalcook Jun. 2 at 1:44 PM

$ORIC how does this compare to $JANX and $VIR?

1 · Reply

GSP Jun. 2 at 1:00 PM

Video title should say June 2nd, not the 1st. Apologies. $SPY $RRGB $ORIC $TNGX $LTBR

0 · Reply

leon_dedrick May. 30 at 6:39 PM

$ORIC This will quietly creep over 10.00 the next month

0 · Reply

PenkeTrading May. 30 at 12:00 PM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Oric Pharmaceuticals Inc. Is that bullish or bearish? $ORIC #Oric #RsiOverbought #NASDAQ

0 · Reply

GSP May. 30 at 11:34 AM

$SPY $ZEO $ORIC $U $SGBX

0 · Reply

PaulLaurent May. 30 at 5:48 AM

0 · Reply

StocktwitsNews May. 30 at 3:59 AM

Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial $ORIC https://stocktwits.com/news/equity/markets/oric-pharma-stock-hits-3-month-high-on-promising-results-in-prostate-cancer-trial/ch0M1zSRbMf

0 · Reply

fallondpicks May. 29 at 9:30 PM

22 #stockbreakouts $AI (gap and base), $ORIC (gap), $SPTN (base), $VEEV (gap). Five sub-$1.

1 · Reply

hiloSF May. 29 at 7:08 PM

"8 Trading Tips for Gap Up Stocks: Understanding Stock Chart Technical Analysis and Trading Strategies" 🐸🐾 👉 https://dreamchaserx.com/8-trading-tips-for-gap-up-stocks $STUDY $ELF $BBW $ZEO $ORIC #swingtradingstrategy #stockchartanalysis #tradingtips #howtotradestocks #StockWatch

0 · Reply

IndicatorGator May. 29 at 6:25 PM

From last night's Watchlist. Catching 10% to 30% or more was possible today. Hope everyone caught some profit. $HCTI .0074 to .0129 (74%) $NAOV $1.17 to $1.81 (54%) $HTCR .67 to $1 (49%) $IMNN 1.60 to $2.15 (34%) $ORIC $6.70 to $8.44 (26%)

0 · Reply

SelectiveTrader May. 29 at 6:00 PM

Good afternoon, my afternoon day trade watch list part 2: $IMNN $MLGO $SBET $WETO $ORIC

0 · Reply

DARKP00L May. 29 at 5:54 PM

$ORIC 13:52 on May. 29 2025 Oric Pharmaceuticals shares are trading higher after the company reported positive efficacy and safety data from its early-stage prostate cancer candidate and announced a $125 million private placement. #tradeideas

0 · Reply

YouVSYou May. 29 at 5:42 PM

$EOSE demand zones forming $ORIC $WETO $STRM $IMCC Intraday demand zone identifying

0 · Reply

Rounderssss4 May. 29 at 5:39 PM

$ORIC first gap at 9.85 see you there

0 · Reply

UnicornPicks May. 29 at 4:51 PM

Some of our free ideas on the D. $IMCC $ORIC $ALZN

0 · Reply

JoeAlerts May. 29 at 4:47 PM

$ORIC Keep an eye on this, up trending on scanners should there be a dip and rip or continuation

0 · Reply

Phantom_OfThe_Retrrrd May. 29 at 4:25 PM

Couldn't agree more! Grabbed some $SBET when they called it before open today. That's the second time they've called it this week and both times were bangers! That $ORIC overnight was crazy too! I keep their group on my screen anytime I'm trading for sure.

0 · Reply

ZacksResearch May. 29 at 4:13 PM

$ORIC pops 20% on promising prostate cancer trial data! ORIC-944 shows early efficacy in mCRPC patients, with 59% PSA50 response initially and 47% confirmed rate. Plus, ORIC's safety remains solid with mild to moderate adverse events. Full trial details and future plans here 👉 https://www.zacks.com/commentary/2479125/oric-stock-surges-on-upbeat-initial-data-from-prostate-cancer-study?cid=sm-stocktwits-2-2479125-body&ADID=SYND_STOCKTWITS_TWEET_2_2479125_BODY

0 · Reply

Market Cap	820.71M
Revenue (ttm)	0.00
Net Income (ttm)	-127.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,010,944
Avg Vol	1,228,436
Day's Range	N/A - N/A
Shares Out	85.22M
Stochastic %K	78%
Beta	1.49
Analysts	Strong Sell
Price Target	$18.90